Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novavax (GB:0A3S)
LSE:0A3S
Novavax (0A3S) Share Price & Analysis
14 Followers
0A3S Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.53 - $11.32
Previous Close$4.28
Volume31.43K
Average Volume (3M)139.16K
Market Cap
$586.40M
Enterprise Value$246.98M
Total Cash (Recent Filing)$568.50M
Total Debt (Recent Filing)$229.08M
Price to Earnings (P/E)-0.8
Beta1.86
Next Earnings
May 07, 2024EPS Estimate
-$1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.54
Shares Outstanding139,953,143
10 Day Avg. Volume3,957
30 Day Avg. Volume139,157
Standard Deviation0.53
R-Squared0.20
Alpha0.19
Financial Highlights & Ratios
Price to Book (P/B)-0.65
Price to Sales (P/S)37.56
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.25
Enterprise Value/Gross Profit0.39
Enterprise Value/Ebitda-0.76
Forecast
1Y Price Target
$9.75Price Target Upside137.92% Upside
Rating ConsensusHold
Number of Analyst Covering4
Novavax News
Bulls Say, Bears Say
Bulls Say
Financial HealthSettlement with Gavi removes operational uncertainty, which has been a long-term overhang on stock.
Market PenetrationStrategic prioritization of key ex-US markets, including U.K. commercial market, resulting in delivery of ~$1B APAs through 2026.
Product DevelopmentNovavax' COVID-19 vaccine elicits broad and long-lived immune responses with a favorable reactogenicity profile.
Bears Say
Earnings4Q23 Top/Bottomline Miss, Lowered 1Q Guide Not a Huge Surprise
Market PenetrationPenetration into the commercial COVID-19 vaccine market was lower than anticipated.
Product DemandMulti-dose format of Novavax vaccine could lead to pharmacy stock delays or avoidance, potentially resulting in inventory write-downs.
---
Options Prices
Currently, No data available
---
Ownership Overview
17.02% Insiders
13.76% Mutual Funds
23.31% Other Institutional Investors
45.91% Public Companies and
Individual Investors
0A3S FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest share price was $3.53 and its highest was $11.31 in the past 12 months.
What is Novavax’s market cap?
Currently, no data Available
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is May 07, 2024 which is in 10 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Feb 28, 2024. The company reported -$1.44 earnings per share for the quarter, missing the consensus estimate of -$0.448 by -$0.992.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -$1.06.
How many shares outstanding does Novavax have?
Novavax has 139,953,140 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$1.44 in its last earnings report, missing expectations of -$0.448. Following the earnings report the stock price went down -25.541%.
Which hedge fund is a major shareholder of Novavax?
Among the largest hedge funds holding Novavax’s share is Coatue Management, LLC. It holds Novavax’s shares valued at 7M.
---
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$9.75 (137.92% Upside)
$9.75 (137.92% Upside)
Blogger Sentiment
Bullish
GB:0A3S Sentiment 79%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.86%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a late-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. Its vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
---
0A3S Company Deck
---
0A3S Earnings Call
Q4 2024
0:00 / 0:00
---
0A3S Stock 12 Months Forecast
Average Price Target
$9.75
▲(137.92% Upside)
Technical Analysis
Best Analysts Covering 0A3S
1 Year
1 Year Success Rate
16/34 ratings generated profit
1 Year Average Return
+153.14%
reiterated a buy rating 2 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +153.14% per trade.
---